Publications by authors named "Shu-Bin Hong"
Article Synopsis
- This clinical trial explored the effectiveness of adding sintilimab, a PD-1 inhibitor, to standard chemoradiotherapy for patients with high-risk, locoregionally advanced nasopharyngeal carcinoma.
- Results showed that the sintilimab group had significantly better event-free survival rates compared to the standard therapy group at a median follow-up of nearly 42 months.
- The trial also reported that a high percentage of patients experienced grade 3-4 adverse events, indicating a need for monitoring side effects in this treatment approach.
Objective: Guidelines for screening and diagnosis of gestational diabetes mellitus (GDM) have been updated in the past several years, and various inconsistencies exist across these guidelines. Moreover, the quality of these updated guidelines has not been clarified. We thus conducted this systematic review to evaluate the relationship between the quality and detailed recommendations of these guidelines.
View Article and Find Full Text PDFLiraglutide is administered as glucagon-like peptide-1 (GLP-1) receptor agonist for diabetic patients and can protect pancreatic β-cells by inhibiting their apoptosis. MicroRNA-139-5p (miRNA-139-5p) participates in the regulation of cancer cell apoptosis. However, it is not clear whether miR-139-5p contributes to the anti-apoptotic effect of liraglutide in β-cells.
View Article and Find Full Text PDF